약물감시 및 약물 안전 소프트웨어 시장 : 소프트웨어 유형별, 조직 규모별, 약물 안전 감시 유형별, 도입 형태별, 임상시험 단계별, 최종 사용자별, 용도별 시장 예측(2026-2032년)

The Pharmacovigilance & Drug Safety Software Market is projected to grow by USD 531.33 million at a CAGR of 6.28% by 2032.

Pharmacovigilance and drug safety software has become a strategic compliance backbone for pharmaceutical, biotechnology, medical device, and contract research organizations. The sector is being shaped by expanding adverse event reporting volumes, stricter post-marketing surveillance expectations, decentralized clinical trials, and the need to manage safety data across global regulatory systems such as FDA FAERS, EMA EudraVigilance, and WHO VigiBase.

Modern pharmacovigilance platforms support case intake, ICSR processing, signal detection, aggregate reporting, literature monitoring, benefit-risk management, and regulatory submission workflows. Demand is strongest where organizations must comply with ICH E2B(R3), 21 CFR Part 11, EU GVP modules, GDPR, validated GxP software requirements, MedDRA coding, WHODrug dictionaries, and inspection-ready audit trails while reducing cycle times and improving data quality.

Transformative Shifts in the Pharmacovigilance Software Landscape

The pharmacovigilance software landscape is shifting from document-centric safety operations to data-centric, interoperable, and automation-enabled ecosystems. Regulators increasingly expect structured submissions, traceable case narratives, validated workflows, and proactive risk management, encouraging sponsors to replace fragmented legacy systems with cloud-based drug safety platforms.

Another major shift is the convergence of clinical safety, post-marketing surveillance, real-world evidence, medical information, and quality management. Organizations are prioritizing platforms that integrate electronic health records, call center intake, patient support programs, literature sources, social media screening where permitted, and regulatory intelligence to create a unified safety operating model. This transition is also increasing emphasis on cybersecurity, data residency, multilingual workflows, and standardized exchange formats for global adverse event reporting.

Cumulative Impact of Artificial Intelligence on Drug Safety

Artificial intelligence is creating measurable operational value in pharmacovigilance by supporting adverse event triage, duplicate detection, MedDRA coding assistance, narrative generation, literature screening, translation support, case validity assessment, and signal prioritization. Natural language processing is particularly relevant because safety teams process unstructured data from clinical notes, scientific publications, emails, contact-center transcripts, medical inquiries, and patient-reported sources.

The cumulative impact is not full replacement of medical judgment but better productivity, consistency, and scalability across case processing and signal management. Leading organizations are implementing human-in-the-loop AI with validation controls, model monitoring, explainability, data lineage, bias checks, and governance aligned with GxP expectations, EU AI Act direction, FDA digital health thinking, and global regulatory scrutiny of automated decision support. Verified deployment practices increasingly require documented intended use, performance testing, change control, and ongoing quality oversight.

Key Regional Insights Across Global Pharmacovigilance Markets

North America remains a high-adoption region for pharmacovigilance and drug safety software because the United States has mature FDA reporting infrastructure, mandatory electronic safety submissions, strong use of real-world data through programs such as Sentinel, and a large concentration of global pharmaceutical sponsors, biotechnology firms, CROs, and safety service providers. Canada also supports demand through Health Canada safety reporting expectations, bilingual labeling and documentation needs, and alignment with international adverse event reporting practices.

Europe is shaped by EMA EudraVigilance, EU Good Pharmacovigilance Practices, GDPR, the need for qualified person for pharmacovigilance oversight, and harmonized yet country-specific enforcement across Germany, France, Italy, Spain, and the broader European Economic Area. Asia-Pacific is expanding in strategic importance as China, India, Japan, South Korea, and Australia strengthen local safety reporting rules, support more global clinical development activity, and require configurable workflows for language, causality, literature monitoring, and local regulatory submissions. Latin America is progressing through stronger national regulatory oversight, particularly in Brazil and Mexico, where pharmacovigilance modernization supports both imported and locally manufactured medicines. The Middle East is advancing through healthcare digitization, national drug safety centers, and stronger post-marketing surveillance expectations, while Africa shows rising demand as regulators improve adverse event reporting capacity, strengthen medicine safety systems, and participate in global safety monitoring networks.

Key Group Insights for ASEAN, GCC, EU, BRICS, G7, and NATO

ASEAN markets are advancing pharmacovigilance capabilities as member states align with international safety reporting principles while maintaining local language, labeling, licensing, and submission requirements. This creates demand for configurable drug safety software that supports affiliate workflows, distributor oversight, and cross-border safety data exchange. The GCC is investing in healthcare digitization and regulatory modernization, making validated cloud safety systems increasingly relevant for regional pharmacovigilance teams managing Gulf-specific reporting rules, Arabic-language considerations, and centralized portfolio governance.

The European Union is one of the most structured pharmacovigilance environments due to centralized EMA systems, EU GVP modules, EudraVigilance obligations, and strong data protection requirements under GDPR. BRICS markets are strategically important because of large patient populations, expanding domestic pharmaceutical manufacturing, growing clinical trial activity, and increasing regulator focus on post-marketing safety. G7 markets typically emphasize mature compliance, advanced inspection readiness, cyber resilience, validated automation, and integration of real-world evidence into benefit-risk assessment. NATO-aligned markets further prioritize continuity of safety operations, data sovereignty, secure cloud infrastructure, and resilient pharmacovigilance processes across complex multinational portfolios.

Key Country Insights for Leading Pharmacovigilance Software Markets

The United States leads in enterprise-scale pharmacovigilance adoption, supported by FDA FAERS, electronic ICSR expectations, REMS requirements, 21 CFR Part 11 validation, Sentinel-related real-world evidence activity, and extensive outsourcing networks. Canada continues to advance structured safety compliance through Health Canada requirements and bilingual operational needs, while Mexico is strengthening pharmacovigilance practices under national health authority oversight. Brazil remains especially important in Latin America due to ANVISA supervision, active local manufacturing, and broad post-marketing surveillance requirements.

In Europe, the United Kingdom, Germany, France, Italy, and Spain prioritize EudraVigilance connectivity, qualified person for pharmacovigilance obligations, risk management planning, periodic safety update reporting, and GDPR-compliant safety data handling. The United Kingdom also maintains distinct post-Brexit regulatory pathways through MHRA oversight, while Russia requires attention to local reporting rules, language requirements, and data localization considerations. In Asia-Pacific, China, India, Japan, Australia, and South Korea are key drug safety software markets because of large patient populations, active clinical research, evolving regulatory systems, and rising demand for multilingual, locally configurable safety platforms. China is strengthening drug safety oversight through its national regulatory framework, India supports large-scale pharmacovigilance activity through expanding clinical research and public safety programs, Japan requires precise local reporting and Japanese-language workflows, Australia aligns closely with international safety standards under TGA oversight, and South Korea continues to mature its digital regulatory and adverse event reporting capabilities.

Actionable Recommendations for Pharmacovigilance Industry Leaders

Industry leaders should prioritize pharmacovigilance software platforms that combine regulatory compliance, workflow automation, interoperability, cyber resilience, and validated AI governance. Selection criteria should include ICH E2B(R3) readiness, audit trails, configurable reporting rules, MedDRA and WHODrug support, case quality checks, literature monitoring, signal management, aggregate reporting, regulatory submission management, and secure integration with clinical, medical information, quality, and enterprise data systems.

Executives should also invest in operating model redesign, not only technology replacement. High-performing safety organizations standardize global processes, define clear human oversight for AI-assisted tasks, maintain inspection-ready documentation, and use analytics to monitor compliance metrics such as case processing timelines, follow-up completion, duplicate rates, narrative quality, submission success, and signal review performance. Leaders should also establish data governance, vendor oversight, validation lifecycle management, disaster recovery planning, and role-based training to ensure pharmacovigilance modernization remains compliant, scalable, and sustainable.

Research Methodology for Pharmacovigilance Software Insights

This executive summary is grounded in secondary research from regulatory agencies, international safety standards, pharmacovigilance guidance, public health authority documentation, industry best practices, and observed technology adoption patterns across life sciences organizations. Key references include FDA, EMA, MHRA, Health Canada, WHO Programme for International Drug Monitoring, ICH safety guidelines, EU Good Pharmacovigilance Practices, national pharmacovigilance regulations, and publicly available guidance on electronic submissions, validation, data protection, and post-marketing surveillance.

The analysis evaluates demand drivers, compliance obligations, regional adoption patterns, technology innovation, AI governance, interoperability needs, and enterprise procurement priorities. Insights are synthesized to support strategic decision-making for software vendors, pharmaceutical sponsors, biotechnology companies, medical device firms, CROs, regulatory teams, and healthcare stakeholders seeking reliable pharmacovigilance modernization. No market sizing, forecasting, or market share assumptions are applied.

Conclusion on the Future of Pharmacovigilance Software

Pharmacovigilance and drug safety software is moving from a back-office compliance tool to a mission-critical intelligence platform for patient safety, regulatory trust, and portfolio risk management. Rising case complexity, globalized clinical development, post-marketing evidence requirements, and increasing regulatory scrutiny are accelerating adoption of cloud, automation, analytics, and AI-assisted workflows.

Organizations that modernize safety operations with validated, interoperable, secure, and regionally adaptable platforms will be better positioned to meet inspection expectations, shorten case cycle times, strengthen signal detection, and support safer therapies worldwide. The most successful strategies will balance automation with medical expertise, data governance, quality management, and sustained regulatory alignment across the full pharmacovigilance lifecycle.

Table of Contents

1. Preface

• 1.1. Objectives of the Study
• 1.2. Market Definition
• 1.3. Market Segmentation & Coverage
• 1.4. Years Considered for the Study
• 1.5. Currency Considered for the Study
• 1.6. Language Considered for the Study
• 1.7. Key Stakeholders

2. Research Methodology

• 2.1. Introduction
• 2.2. Research Design
  • 2.2.1. Primary Research
  • 2.2.2. Secondary Research
• 2.3. Research Framework
  • 2.3.1. Qualitative Analysis
  • 2.3.2. Quantitative Analysis
• 2.4. Market Size Estimation
  • 2.4.1. Top-Down Approach
  • 2.4.2. Bottom-Up Approach
• 2.5. Data Triangulation
• 2.6. Research Outcomes
• 2.7. Research Assumptions
• 2.8. Research Limitations

3. Executive Summary

• 3.1. Introduction
• 3.2. CXO Perspective
• 3.3. Market Size & Growth Trends
• 3.4. Market Share Analysis, 2025
• 3.5. FPNV Positioning Matrix, 2025
• 3.6. New Revenue Opportunities
• 3.7. Next-Generation Business Models
• 3.8. Industry Roadmap

4. Market Overview

• 4.1. Introduction
• 4.2. Industry Ecosystem & Value Chain Analysis
  • 4.2.1. Supply-Side Analysis
  • 4.2.2. Demand-Side Analysis
  • 4.2.3. Stakeholder Analysis
• 4.3. Market Dynamics
  • 4.3.1. Key Drivers
  • 4.3.2. Key Restraints
  • 4.3.3. Key Opportunities
  • 4.3.4. Key Challenges
• 4.4. Porter's Five Forces Analysis
• 4.5. PESTLE Analysis
• 4.6. Market Outlook
  • 4.6.1. Near-Term Market Outlook (0-2 Years)
  • 4.6.2. Medium-Term Market Outlook (3-5 Years)
  • 4.6.3. Long-Term Market Outlook (5-10 Years)
• 4.7. Go-to-Market Strategy

5. Market Insights

• 5.1. Consumer Insights & End-User Perspective
• 5.2. Consumer Experience Benchmarking
• 5.3. Opportunity Mapping
• 5.4. Distribution Channel Analysis
• 5.5. Pricing Trend Analysis
• 5.6. Regulatory Compliance & Standards Framework
• 5.7. ESG & Sustainability Analysis
• 5.8. Disruption & Risk Scenarios
• 5.9. Return on Investment & Cost-Benefit Analysis

6. Cumulative Impact of Artificial Intelligence 2026

7. Pharmacovigilance & Drug Safety Software Market, by Software Type

• 7.1. Adverse Event Reporting Software
• 7.2. Drug Safety Audits Software
• 7.3. Issue Tracking Software
• 7.4. Risk Management Software
• 7.5. Signal Detection Software
• 7.6. Case Data Analysis Software
• 7.7. Compliance & Regulatory Reporting Software

8. Pharmacovigilance & Drug Safety Software Market, by Organization Size

• 8.1. Large Enterprise
• 8.2. Small And Medium Enterprise

9. Pharmacovigilance & Drug Safety Software Market, by Pharmacovigilance Type

• 9.1. In-House Pharmacovigilance
• 9.2. Outsourced Pharmacovigilance

10. Pharmacovigilance & Drug Safety Software Market, by Deployment Mode

• 10.1. Cloud
  • 10.1.1. Private Cloud
  • 10.1.2. Public Cloud
• 10.2. On Premise

11. Pharmacovigilance & Drug Safety Software Market, by Clinical Trial Phase

• 11.1. Preclinical
• 11.2. Phase I
• 11.3. Phase II
• 11.4. Phase III
• 11.5. Phase IV

12. Pharmacovigilance & Drug Safety Software Market, by End User

• 12.1. Contract Research Organizations
• 12.2. Pharmaceutical And Biotech Companies
• 12.3. Biotechnology Companies
• 12.4. Medical Device Manufacturers
• 12.5. Regulatory Authorities
• 12.6. Hospitals & Healthcare Providers

13. Pharmacovigilance & Drug Safety Software Market, by Application

• 13.1. Adverse Event Case Management
• 13.2. Aggregate Reporting
• 13.3. Risk Communication
• 13.4. Risk Management

14. Pharmacovigilance & Drug Safety Software Market, by Region

• 14.1. Asia-Pacific
• 14.2. North America
• 14.3. Latin America
• 14.4. Europe
• 14.5. Middle East
• 14.6. Africa

15. Pharmacovigilance & Drug Safety Software Market, by Group

• 15.1. ASEAN
• 15.2. GCC
• 15.3. European Union
• 15.4. BRICS
• 15.5. G7
• 15.6. NATO

16. Pharmacovigilance & Drug Safety Software Market, by Country

• 16.1. United States
• 16.2. Canada
• 16.3. Mexico
• 16.4. Brazil
• 16.5. United Kingdom
• 16.6. Germany
• 16.7. France
• 16.8. Russia
• 16.9. Italy
• 16.10. Spain
• 16.11. China
• 16.12. India
• 16.13. Japan
• 16.14. Australia
• 16.15. South Korea

17. Competitive Landscape

• 17.1. Market Concentration Analysis, 2025
  • 17.1.1. Concentration Ratio (CR)
  • 17.1.2. Herfindahl Hirschman Index (HHI)
• 17.2. Recent Developments & Impact Analysis, 2025
• 17.3. Product Portfolio Analysis, 2025
• 17.4. Benchmarking Analysis, 2025

18. Company Profiles

• 18.1. 4C Pharma Solutions
• 18.2. AB Cube S.A.S.
• 18.3. Accenture PLC
• 18.4. Anju Software, Inc.
• 18.5. ArisGlobal LLC
• 18.6. Certara, Inc.
• 18.7. Clarivate
• 18.8. Clinevo Technologies Private Limited
• 18.9. Cloudbyz, Inc.
• 18.10. Cognizant Technology Solutions Corporation
• 18.11. Ennov SAS
• 18.12. Ergomed PLC
• 18.13. Extedo GmbH
• 18.14. Freyr Software Services Pvt. Ltd.
• 18.15. Indegene Inc.
• 18.16. Infosys Limited
• 18.17. IQVIA Inc.
• 18.18. NUVO Consultancy
• 18.19. Oracle Corporation
• 18.20. PureSoftware Limited
• 18.21. Sarjen Systems Private Limited
• 18.22. Sparta Systems, Inc.
• 18.23. Tepsivo Oy
• 18.24. TriNetX, LLC
• 18.25. United BioSource LLC
• 18.26. Wipro Limited